Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Avelumab + Cofetuzumab pelidotin|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Avelumab||Bavencio||MSB0010718C||Immune Checkpoint Inhibitor 94 PD-L1/PD-1 antibody 62||Bavencio (avelumab) is a monoclonal antibody binds to human immunosuppressive ligand programmed death-ligand 1 (PD-L1, CD274) and blocks protein signaling, resulting in immune regulation and antitumor immunity (PMID: 26014098). Bavencio (avelumab) is FDA-approved for use in adult and pediatric patients of 12 years or older with metastatic Merkel cell carcinoma, as maintenance therapy in locally advanced or metastatic urothelial carcinoma (UC), in locally advanced or metastatic UC that progressed following chemotherapy, and in combination with axitinib as first-line therapy in advanced renal cell carcinoma (FDA.gov).|
|Cofetuzumab pelidotin||h6M24-vc0101|PTK7-targeted antibody-drug conjugate|ABBV-647|PF-06647020||Cofetuzumab pelidotin (PF-06647020) is an antibody-drug conjugate comprising a monoclonal antibody against PTK7 linked to Aur0101, which delivers the cytotoxic agent to PTK7-expressing tumor cells, leading to cell death (PMID: 28077676).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02222922||Phase I||Avelumab + Cofetuzumab pelidotin Fluconazole Cofetuzumab pelidotin||A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors||Completed|